top of page

Top Scientists Leading
Tomorrow's Treatments

Ymmunobio is committed to developing preclinical breakthroughs toward improving how cancer therapies are developed.

Dr. Katrin Rupalla founded Ymmunobio in 2021 as a way to advance developments in CEACAM1 and NPTXR research. Since that time, Ymmunobio has assembled a distinguished team of scientific and clinical leaders who are united in transforming how cancer and autoimmune diseases are treated.

Executive Team

Peter Schiemann, PhD

Chief Executive Officer

Michel Janicot, PhD

Chief Development Officer

Angela S. Gibbs, MBA

Chief Business Officer

Selena (2)_edited.jpg

Selena Blackmore

Director, Business Operations

Scientific Advisory Board

Katrin Rupalla, PhD

Founder, Ymmunobio

Head, Global Regulatory Affairs, Janssen Research & Development

Iris Helfrich, PhD

Professor, Experimental Dermato-Oncology,

University of Munich

Mitsuro Kanda, MD, PhD

Professor

Gastroenterological Surgery

University of Nagoya, Japan

Vishal Khairnar, PhD

CEACAM Expert

Martin 2 NR.jpg

Martin Zuzulo

Chief Operating Officer

Prof. Keith Skubitz, MD

Professor, Hematology, University of Minnesota

Board of Directors

Peter Schiemann, PhD

Chairman

Jürgen Heitmann, PhD

Non-Executive Director

Caroline Germa, MD

Non-Executive Director

bottom of page